Home » SOLVAY'S TRICOR Q3 U.S. SALES UP 8.1 PCT
SOLVAY'S TRICOR Q3 U.S. SALES UP 8.1 PCT
U.S. sales for Solvay's (SOLBt.BR: Quote, Profile, Research) lipid disorder treatment Tricor rose 8.1 percent in the third quarter to $225 million (188.4 million euros), according to figures released by Abbot Laboratories (ABT.N: Quote, Profile, Research).
Abbott, which markets the drug in the United States for the Belgian drug and chemical company, published the figures in its earnings report on Wednesday.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May